ATE147385T1 - Chinuclidin derivat als substanz p antagonist - Google Patents
Chinuclidin derivat als substanz p antagonistInfo
- Publication number
- ATE147385T1 ATE147385T1 AT93917176T AT93917176T ATE147385T1 AT E147385 T1 ATE147385 T1 AT E147385T1 AT 93917176 T AT93917176 T AT 93917176T AT 93917176 T AT93917176 T AT 93917176T AT E147385 T1 ATE147385 T1 AT E147385T1
- Authority
- AT
- Austria
- Prior art keywords
- pct
- substance
- antagonist
- quinuclidine derivative
- date
- Prior art date
Links
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 title abstract 2
- 239000003890 substance P antagonist Substances 0.000 title abstract 2
- PKOQGZGCLCOZTR-CONSDPRKSA-N (2s,3s)-2-benzhydryl-n-[(2-methoxy-5-propylphenyl)methyl]-1-azabicyclo[2.2.2]octan-3-amine Chemical compound CCCC1=CC=C(OC)C(CN[C@@H]2[C@@H](N3CCC2CC3)C(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 PKOQGZGCLCOZTR-CONSDPRKSA-N 0.000 abstract 1
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Addiction (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97524492A | 1992-11-12 | 1992-11-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE147385T1 true ATE147385T1 (de) | 1997-01-15 |
Family
ID=25522825
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT93917176T ATE147385T1 (de) | 1992-11-12 | 1993-07-19 | Chinuclidin derivat als substanz p antagonist |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5886009A (de) |
| EP (1) | EP0668863B1 (de) |
| JP (1) | JP2668164B2 (de) |
| KR (1) | KR950704311A (de) |
| CN (1) | CN1034732C (de) |
| AT (1) | ATE147385T1 (de) |
| AU (1) | AU676489B2 (de) |
| CA (1) | CA2149242C (de) |
| DE (1) | DE69307340T2 (de) |
| DK (1) | DK0668863T3 (de) |
| ES (1) | ES2096312T3 (de) |
| FI (1) | FI934983A7 (de) |
| GR (1) | GR3022459T3 (de) |
| IL (1) | IL107495A (de) |
| MX (1) | MX9307062A (de) |
| MY (1) | MY130145A (de) |
| NZ (1) | NZ254604A (de) |
| WO (1) | WO1994011368A1 (de) |
| ZA (1) | ZA938421B (de) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6387925B1 (en) * | 1999-06-01 | 2002-05-14 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions |
| US6262067B1 (en) * | 1999-06-22 | 2001-07-17 | Pfizer Inc. | Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions |
| KR100885986B1 (ko) | 1999-11-03 | 2009-03-03 | 에이엠알 테크놀로지, 인크. | 노르에피네프린, 도파민 및 세로토닌의 재흡수를 방지하기위한 아릴 및 헤테로아릴 치환된테트라하이드로이소퀴놀린 및 이들의 용도 |
| US7163949B1 (en) | 1999-11-03 | 2007-01-16 | Amr Technology, Inc. | 4-phenyl substituted tetrahydroisoquinolines and use thereof |
| DE10001785A1 (de) * | 2000-01-18 | 2001-07-19 | Boehringer Ingelheim Pharma | NK¶1¶-Rezeptor-Antagonisten zur Behandlung des Restless Legs Syndroms |
| CA2415532C (en) | 2000-07-11 | 2010-05-11 | Albany Molecular Research, Inc. | Novel 4-phenyl substituted tetrahydroisoquinolines therapeutic use thereof |
| US6861526B2 (en) * | 2002-10-16 | 2005-03-01 | Pfizer Inc. | Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine |
| EP1689721B1 (de) * | 2003-11-26 | 2010-07-14 | Pfizer Products Inc. | Aminopyrazolderivate als gsk-3-inhibitoren |
| LT1713504T (lt) * | 2004-01-30 | 2017-09-11 | Zoetis Services Llc | Antimikrobinis konservantas, skirtas multi-dozinėms kompozicijoms, panaudojant beta-ciklodekstrinus, skirtas skystoms vaisto formoms |
| KR101389246B1 (ko) | 2004-07-15 | 2014-04-24 | 브리스톨-마이어스스퀴브컴파니 | 아릴- 및 헤테로아릴-치환된 테트라히드로이소퀴놀린, 및 이것의 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도 |
| EP1888050B1 (de) | 2005-05-17 | 2012-03-21 | Merck Sharp & Dohme Ltd. | Cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropansäure zur Behandlug von Krebs |
| ZA200800440B (en) | 2005-07-15 | 2009-12-30 | Amr Technology Inc | Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
| US8293900B2 (en) | 2005-09-29 | 2012-10-23 | Merck Sharp & Dohme Corp | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
| GB0603041D0 (en) | 2006-02-15 | 2006-03-29 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP2698157B1 (de) | 2006-09-22 | 2015-05-20 | Merck Sharp & Dohme Corp. | Verfahren zur Behandlung von Fettsäure-Synthese-Hemmern |
| US20110218176A1 (en) | 2006-11-01 | 2011-09-08 | Barbara Brooke Jennings-Spring | Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development |
| CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| EP2805945B1 (de) | 2007-01-10 | 2019-04-03 | MSD Italia S.r.l. | Amidsubstituierte Indazole als Poly-(ADP-Ribose)-Polymerase (PARP)-Hemmer |
| US8106086B2 (en) | 2007-04-02 | 2012-01-31 | Msd K.K. | Indoledione derivative |
| US8389553B2 (en) | 2007-06-27 | 2013-03-05 | Merck Sharp & Dohme Corp. | 4-carboxybenzylamino derivatives as histone deacetylase inhibitors |
| KR20100126467A (ko) | 2008-03-03 | 2010-12-01 | 타이거 파마테크 | 티로신 키나아제 억제제 |
| US9156812B2 (en) | 2008-06-04 | 2015-10-13 | Bristol-Myers Squibb Company | Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| CN102638982B (zh) | 2009-05-12 | 2015-07-08 | 百时美施贵宝公司 | (S)-7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉的晶型及其用途 |
| KR101830447B1 (ko) | 2009-05-12 | 2018-02-20 | 알바니 몰레큘라 리써치, 인크. | 7-(［1,2,4］트리아졸로［1,5-α］피리딘-6-일)-4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로이소퀴놀린 및 이의 용도 |
| EP2429295B1 (de) | 2009-05-12 | 2013-12-25 | Albany Molecular Research, Inc. | Aryl-, heteroaryl- und heterocyclen-substituierte tetrahydroisochinoline und ihre verwendung |
| EP2488028B1 (de) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung |
| WO2011163330A1 (en) | 2010-06-24 | 2011-12-29 | Merck Sharp & Dohme Corp. | Novel heterocyclic compounds as erk inhibitors |
| CN107090456B (zh) | 2010-08-02 | 2022-01-18 | 瑟纳治疗公司 | 使用短干扰核酸的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1基因表达的抑制 |
| JP2013537423A (ja) | 2010-08-17 | 2013-10-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸（ｓｉＮＡ）を用いたＢ型肝炎ウイルス（ＨＢＶ）遺伝子発現のＲＮＡ干渉媒介性阻害 |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012030685A2 (en) | 2010-09-01 | 2012-03-08 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2615916B1 (de) | 2010-09-16 | 2017-01-04 | Merck Sharp & Dohme Corp. | Kondensierte pyrazolderivate als neue erk-hemmer |
| DK2632472T3 (en) | 2010-10-29 | 2018-03-19 | Sirna Therapeutics Inc | RNA INTERFERENCE-MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERRING NUCLEIC ACIDS (SINA) |
| WO2012087772A1 (en) | 2010-12-21 | 2012-06-28 | Schering Corporation | Indazole derivatives useful as erk inhibitors |
| EP2699568A1 (de) | 2011-04-21 | 2014-02-26 | Piramal Enterprises Limited | Kristalline form eines morpholinsulfonylindolderivat-salzes und verfahren zu seiner herstellung |
| WO2013063214A1 (en) | 2011-10-27 | 2013-05-02 | Merck Sharp & Dohme Corp. | Novel compounds that are erk inhibitors |
| EP2844261B1 (de) | 2012-05-02 | 2018-10-17 | Sirna Therapeutics, Inc. | Sina-zusammensetzungen |
| CN105050598B (zh) | 2012-09-28 | 2018-04-27 | 默沙东公司 | 作为erk抑制剂的新型化合物 |
| JP6440625B2 (ja) | 2012-11-14 | 2018-12-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | 精神分裂病を処置するための方法および組成物 |
| RS56680B1 (sr) | 2012-11-28 | 2018-03-30 | Merck Sharp & Dohme | Kompozicije i postupci za lečenje kancera |
| US8846657B2 (en) | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| EP3041938A1 (de) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Kreisförmige polynukleotide |
| US10975084B2 (en) | 2016-10-12 | 2021-04-13 | Merck Sharp & Dohme Corp. | KDM5 inhibitors |
| US11098059B2 (en) | 2017-11-08 | 2021-08-24 | Merck Sharp & Dohme Corp. | PRMT5 inhibitors |
| EP3706742B1 (de) | 2017-11-08 | 2023-03-15 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| CA3108388A1 (en) | 2018-08-07 | 2020-02-13 | Merck Sharp & Dohme Corp. | Prmt5 inhibitors |
| EP3833668B1 (de) | 2018-08-07 | 2025-03-19 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
| EP3833667B1 (de) | 2018-08-07 | 2024-03-13 | Merck Sharp & Dohme LLC | Prmt5-inhibitoren |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990005525A1 (en) * | 1988-11-23 | 1990-05-31 | Pfizer Inc. | Quinuclidine derivatives as substance p antagonists |
| EP0532527B1 (de) * | 1990-06-01 | 1994-11-09 | Pfizer Inc. | 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen |
| DE9290063U1 (de) * | 1991-05-31 | 1994-02-24 | Pfizer Inc., New York, N.Y. | Chinuclidin-Derivate |
| ATE195867T1 (de) * | 1991-09-20 | 2000-09-15 | Glaxo Group Ltd | Neue medizinische indikation für tachykinin- antagonisten |
| US5340826A (en) * | 1993-02-04 | 1994-08-23 | Pfizer Inc. | Pharmaceutical agents for treatment of urinary incontinence |
-
1993
- 1993-07-19 US US08/500,958 patent/US5886009A/en not_active Expired - Fee Related
- 1993-07-19 CA CA002149242A patent/CA2149242C/en not_active Expired - Fee Related
- 1993-07-19 AU AU46780/93A patent/AU676489B2/en not_active Ceased
- 1993-07-19 JP JP6502707A patent/JP2668164B2/ja not_active Expired - Lifetime
- 1993-07-19 DK DK93917176.5T patent/DK0668863T3/da active
- 1993-07-19 AT AT93917176T patent/ATE147385T1/de not_active IP Right Cessation
- 1993-07-19 NZ NZ254604A patent/NZ254604A/en unknown
- 1993-07-19 ES ES93917176T patent/ES2096312T3/es not_active Expired - Lifetime
- 1993-07-19 KR KR1019950701877A patent/KR950704311A/ko not_active Ceased
- 1993-07-19 EP EP93917176A patent/EP0668863B1/de not_active Expired - Lifetime
- 1993-07-19 DE DE69307340T patent/DE69307340T2/de not_active Expired - Fee Related
- 1993-07-19 WO PCT/US1993/006624 patent/WO1994011368A1/en not_active Ceased
- 1993-11-04 IL IL10749593A patent/IL107495A/en not_active IP Right Cessation
- 1993-11-09 MY MYPI93002345A patent/MY130145A/en unknown
- 1993-11-11 ZA ZA938421A patent/ZA938421B/xx unknown
- 1993-11-11 CN CN93114371A patent/CN1034732C/zh not_active Expired - Fee Related
- 1993-11-11 MX MX9307062A patent/MX9307062A/es not_active IP Right Cessation
- 1993-11-11 FI FI934983A patent/FI934983A7/fi unknown
-
1997
- 1997-01-31 GR GR970400170T patent/GR3022459T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL107495A0 (en) | 1994-02-27 |
| NZ254604A (en) | 1997-06-24 |
| IL107495A (en) | 1998-12-27 |
| EP0668863B1 (de) | 1997-01-08 |
| FI934983L (fi) | 1994-05-13 |
| FI934983A0 (fi) | 1993-11-11 |
| MY130145A (en) | 2007-06-29 |
| DE69307340D1 (de) | 1997-02-20 |
| JPH07508731A (ja) | 1995-09-28 |
| EP0668863A1 (de) | 1995-08-30 |
| CN1034732C (zh) | 1997-04-30 |
| MX9307062A (es) | 1994-05-31 |
| GR3022459T3 (en) | 1997-04-30 |
| KR950704311A (ko) | 1995-11-17 |
| WO1994011368A1 (en) | 1994-05-26 |
| DK0668863T3 (da) | 1997-06-30 |
| CA2149242A1 (en) | 1994-05-26 |
| DE69307340T2 (de) | 1997-04-24 |
| AU4678093A (en) | 1994-06-08 |
| CA2149242C (en) | 1998-08-04 |
| CN1091134A (zh) | 1994-08-24 |
| ZA938421B (en) | 1995-05-11 |
| US5886009A (en) | 1999-03-23 |
| ES2096312T3 (es) | 1997-03-01 |
| JP2668164B2 (ja) | 1997-10-27 |
| AU676489B2 (en) | 1997-03-13 |
| FI934983A7 (fi) | 1994-05-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE147385T1 (de) | Chinuclidin derivat als substanz p antagonist | |
| FI935134A0 (fi) | Substituerade 3-aminokinuklidiner | |
| MY107157A (en) | Quinuclidine derivatives. | |
| UA27776C2 (uk) | Похідні хінуклідину та їх фармацевтично прийнятні солі, що є антагоністами речовини р у ссавців, фармацевтична композиція, що має антагоністичну дію на речовину р у ссавців | |
| CA2164689A1 (en) | NK-1 Receptor Antagonists and 5HT3 Receptor Antagonists for the Treatment of Emesis | |
| ATE398618T1 (de) | Pharmazeutische zusammensetzungen zur behandlung von zns und anderen krankheiten | |
| BRPI0108977B8 (pt) | compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo | |
| SE9503924D0 (sv) | Novel opioid peptides | |
| DK0738269T3 (da) | Piperidinderivater med PAF-antagonistaktivitet | |
| DE69824313D1 (de) | Sibutramin und orlistat enthaltende pharmazeutische zusammensetzungen | |
| DK0823909T3 (da) | Hidtil ukendte heterocykliske forbindelser | |
| FI954614A0 (fi) | Imidatsolokinoksalinonijohdannaiset EAA-antagonisteina | |
| AU2287197A (en) | Heterocyclic compounds and their preparation and use | |
| NO951865L (no) | Quinuclidin-derivat som substans-P antagonist | |
| DE69811487D1 (de) | Benzoesäurederivate und deren medizinische verwendung | |
| SE9502877D0 (sv) | Novel opioid peptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |